Dr. Mizrahi on Targeting Treatment in Metastatic Colorectal Cancer

In Partnership With:

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Jonathan Mizrahi, MD, fellow at The University of Texas MD Anderson Cancer Center, discusses efforts being made to target treatment for patients with metastatic colorectal cancer (mCRC).

In terms of looking at targeted agents, it's important to incorporate broad-based molecular profiling to all patients upon diagnosis of mCRC, says Mizrahi. One target that is gaining in popularity in terms of treatment options is HER2. In early-phase studies, patients with HER2 amplifications have been shown to benefit greatly from HER2-targeted therapies, including drugs such as trastuzumab (Herceptin), pertuzumab (Perjeta), or antibody-drug conjugates such as ado-trastuzumab emtansine (T-DM1).

There is a lot of area for exploration in patients whose tumors have HER2 amplification. Additionally, for patients with microsatellite instability—high CRC, immunotherapy is moving to the frontline setting. Failing to use this approach in the frontline treatment of this patient population would be a great disservice, concludes Mizrahi.

Related Videos
Brian Henick, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Walter M. Stadler, MD
Susan Domchek, MD, FASCO
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Amy L. Cummings, MD, thoracic oncologist, assistant professor of medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
Experts on BTC
Experts on BTC
In this third episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, highlight the advantages and scope of endoscopic procedures in gastrointestinal cancer.
Related Content